Skip to main content
SpringerLink
Log in

Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer

  • Original Articles
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

Abstract

The prevalence of breast cancer (a hormonally driven neoplasm) in the United States, the potential health benefits of estrogen replacement therapy for postmenopausal women, and the burgeoning research focusing on selective estrogen receptor modulators (SERMs) have resulted in additional complexity in managing breast cancer. In an attempt to clarify existing data, the Society of Surgical Oncology sponsored a symposium entitled “Estrogens and Antiestrogens in Managing the Patient with Breast Cancer” at its 52nd Annual Cancer Symposium. This conference was held in March 1999 and was chaired by Dr. S. Eva Singletary, Professor of Surgery and Chief of the Surgical Breast Section at The University of Texas M. D. Anderson Cancer Center in Houston, Texas. The following is a review of the material presented by the symposium participants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Smith HO, Kammerer-Doak DN, Barbo DM, Sarto GE. Hormone replacement therapy in the menopause: a pro opinion.CA Cancer J Clin 1996;46:343–63.

    Article  PubMed  CAS  Google Scholar 

  2. Grodstein F, Stampfer MJ, Colditz GA, et al. Postmenopausal hormone therapy and mortality.NEJM 1997;336:1769–75.

    Article  PubMed  CAS  Google Scholar 

  3. Arnesson LG, Smeds S, Fagerberg G. Recurrence-free survival in patients with small breast cancers.Eur J Surg 1994;160:271–6.

    PubMed  CAS  Google Scholar 

  4. Dnistrian AM, Schwartz MK, Fracchia AA, Kaufman RJ, Hakes TB, Currie VE. Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients.Cancer 1983;51:803–7.

    Article  PubMed  CAS  Google Scholar 

  5. Dorgan JF, Longcope C, Stephenson HE, et al. Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk.Cancer Epidemiol Biomarkers Prev 1996;5:533–9.

    PubMed  CAS  Google Scholar 

  6. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in premenopausal women.JNCI 1995;87:190–7.

    Article  PubMed  CAS  Google Scholar 

  7. Berrino F, Muti P, Micheli A, et al. Serum sex hormone levels after menopause and subsequent breast cancer.JNCI 1996;88:291–6.

    Article  PubMed  CAS  Google Scholar 

  8. Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies.Cancer Causes Control 1990;1:51–8.

    Article  PubMed  CAS  Google Scholar 

  9. Colditz GA, Hankinson SE, Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.NEJM 1995;332:1589–93.

    Article  PubMed  CAS  Google Scholar 

  10. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.Lancet 1997;350:1047–59.

    Article  Google Scholar 

  11. Magnusson C, Holmberg L, Nordén T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy.Breast Cancer Res Treat 1996;38:325–34.

    Article  PubMed  CAS  Google Scholar 

  12. Stoll BA, Parbhoo S. Treatment of menopausal symptoms in breast cancer patients.Lancet 1988;1: 1278–9.

    Article  PubMed  CAS  Google Scholar 

  13. DiSaia PJ, Odicino F, Grosen EA, Cowan B, Pecorelli S, Wile AG. Hormone replacement therapy in breast cancer.Lancet 1993;342:1232.

    Article  PubMed  CAS  Google Scholar 

  14. Powles TJ, Hickish T, Casey S, O’Brien M. Hormone replacement therapy after breast cancer.Lancet 1993;342:60–1.

    Article  PubMed  CAS  Google Scholar 

  15. Wile AG, Opfell RW, Margileth DA. Hormone replacement therapy in previously treated breast cancer patients.Am J Surg 1993;165:372–5.

    Article  PubMed  CAS  Google Scholar 

  16. Vassilopoulou-Sellin R, Theriault RL, Klein MJ. Estrogen replacement therapy in women with a prior diagnosis and treatment for breast cancer.Gynecol Oncol 1997;65:89–93.

    Article  PubMed  CAS  Google Scholar 

  17. Eden JA, Bush T, Nand S, Wier BG. A case-control study of combined continuous estrogen-progestin replacement therapy among women with a personal history of breast cancer.Menopause 1995;2:67–72.

    Article  Google Scholar 

  18. Newman LA, Kuerer HM, Harper T, et al. Special considerations in breast cancer risk and survival.J Surg Oncol 1999;71:250–60.

    Article  PubMed  CAS  Google Scholar 

  19. Vassilopoulou-Sellin R, Theriault RL. Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer.JNCI Monographs 1994;16:153–9.

    Google Scholar 

  20. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. Perspective: the diagnosis of osteoporosis.J Bone Miner Res 1994;9:1137–41.

    Article  PubMed  CAS  Google Scholar 

  21. Consensus Conference. Osteoporosis.JAMA 1984;252:799–802.

    Article  Google Scholar 

  22. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women.NEJM 1992;327:1637–42.

    PubMed  CAS  Google Scholar 

  23. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study.BMJ 1992;305:556–61.

    Article  PubMed  CAS  Google Scholar 

  24. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial.JAMA 1999;282:637–45.

    Article  PubMed  CAS  Google Scholar 

  25. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method of treatment with illustrative cases.Lancet 1896; 2:104–7.

    Article  Google Scholar 

  26. Lacassagne A. Hormonal pathogenesis of adenocarcinoma of the breast.Am J Cancer 1936;27:217–28.

    Google Scholar 

  27. Jordan VC. Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinoma.Eur J Cancer 1976;12:419–24.

    PubMed  CAS  Google Scholar 

  28. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: an overview of the randomized trials.Lancet 1998;351:1451–67.

    Article  Google Scholar 

  29. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.JNCI 1998;90:1371–88.

    Article  PubMed  CAS  Google Scholar 

  30. Powles T, Eeles R, Ashley S, et al. Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.Lancet 1998;352:98–101.

    PubMed  CAS  Google Scholar 

  31. Veronesi U, Maisonneuve P, Costa A, et al. Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomized women.Lancet 1998;352:93–7.

    PubMed  CAS  Google Scholar 

  32. Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial.JAMA 1999;281:2189–97.

    Article  PubMed  CAS  Google Scholar 

  33. Witliff JL. Steroid hormone receptors in breast cancer.Cancer 1984;53:630–43.

    Article  Google Scholar 

  34. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.JNCI 1996;88:1529–42.

    Article  PubMed  CAS  Google Scholar 

  35. Buzdar AU, Hortobagyi GN. Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy.J Clin Oncol 1998;16:348–53.

    PubMed  CAS  Google Scholar 

  36. Vogel CL, Shemano I, Schoenfelder J, Gams RA, Green MR. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer.J Clin Oncol 1993;11:345–50.

    PubMed  CAS  Google Scholar 

  37. Gams RA, Vogel CL. Toremifene (TOR): an active agent in the management of postmenopausal women with advanced breast cancer refractory to tamoxifen (TAM). Proceedings of the American Society of Clinical Oncology 18: 132a, May 15–18, 1999. Abstract #504.

  38. Roseman BJ, Buzdar AU, Singletary SE. Use of aromatase inhibitors in postmenopausal women with advanced breast cancer.J Surg Oncol 1997;66:215–20.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Box 106, 77030, Houston, TX

    Lisa A. Newman MD & S. Eva Singletary MD

  2. Endocrine Neoplasia, The University of Texas M. D. Anderson Cancer Center, Houston, TX

    Rena V. Sellin MD

  3. Department of Surgery, Emory University School of Medicine, USA

    William C. Wood MD

  4. Department Cancer Research, Columbia Cancer Research Network of Florida, Aventura, FL

    Charles Vogel MD

  5. Department of Surgery, Northwestern University, Chicago, IL

    Monica Morrow MD

Authors
  1. Lisa A. Newman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. William C. Wood MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rena V. Sellin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Monica Morrow MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles Vogel MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Eva Singletary MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S. Eva Singletary MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Newman, L.A., Wood, W.C., Sellin, R.V. et al. Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer. Ann Surg Oncol 7, 568–574 (2000). https://doi.org/10.1007/BF02725335

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02725335

Key Words

Search

Navigation